"Benzhydryl Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which contain the methyl radical substituted with two benzene rings. Permitted are any substituents, but ring fusion to any of the benzene rings is not allowed.
| Descriptor ID |
D001559
|
| MeSH Number(s) |
D02.455.426.559.389.115
|
| Concept/Terms |
Benzhydryl Compounds- Benzhydryl Compounds
- Compounds, Benzhydryl
- Diphenylmethyl Compounds
- Compounds, Diphenylmethyl
|
Below are MeSH descriptors whose meaning is more general than "Benzhydryl Compounds".
Below are MeSH descriptors whose meaning is more specific than "Benzhydryl Compounds".
This graph shows the total number of publications written about "Benzhydryl Compounds" by people in this website by year, and whether "Benzhydryl Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 1 | 4 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2012 | 2 | 2 | 4 |
| 2014 | 4 | 2 | 6 |
| 2015 | 2 | 0 | 2 |
| 2016 | 4 | 0 | 4 |
| 2017 | 1 | 2 | 3 |
| 2018 | 2 | 1 | 3 |
| 2019 | 3 | 1 | 4 |
| 2020 | 4 | 2 | 6 |
| 2021 | 2 | 4 | 6 |
| 2022 | 0 | 2 | 2 |
| 2023 | 2 | 2 | 4 |
| 2024 | 3 | 1 | 4 |
| 2025 | 2 | 0 | 2 |
| 2026 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzhydryl Compounds" by people in Profiles.
-
Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure. Hypertension. 2026 Sep; 83(9):e27036.
-
ToxiTaRGET: a multi-omics database for toxicant-responsive molecular targets. Nat Commun. 2026 May 29; 17(1).
-
Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone. J Am Soc Nephrol. 2026 Sep 01; 37(9):1969-1978.
-
Empagliflozin-mediated protection of heparan sulfate-rich endothelial glycocalyx during vascular inflammation. Biochem Pharmacol. 2026 Jul; 249:117890.
-
Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial. Clin Ther. 2025 Dec; 47(12):1091-1096.
-
Use of SGLT2 inhibitors in pediatric heart failure: a multi-center study. Pediatr Cardiol. 2026 Aug; 47(6):2526-2533.
-
Recent use of consumer and personal care products and exposures to select endocrine disrupting chemicals among urban children with asthma. J Expo Sci Environ Epidemiol. 2024 07; 34(4):637-646.
-
Acute Hemodynamic Effects of Empagliflozin: Are They Relevant to the Clinical Practice? Cardiovasc Drugs Ther. 2024 08; 38(4):769-770.
-
Four weeks SGLT2 inhibition improves beta cell function and glucose tolerance without affecting muscle free fatty acid or glucose uptake in subjects with type 2 diabetes. Basic Clin Pharmacol Toxicol. 2024 May; 134(5):643-656.
-
Dapagliflozin for Atrial Fibrillation. Cardiovasc Drugs Ther. 2024 02; 38(1):1-3.